← FDA DRUG APPROVALS

FDA ANDA · ANDA076603

BETAMETHASONE DIPROPIONATE

Sponsor: CHARTWELL MOLECULAR

APPLICATION
ANDA076603
TYPE
ANDA
ORIGINAL APPROVAL
2004-01-23
LATEST ACTION
2015-06-04
ROUTE
TOPICAL
DOSAGE FORM
CREAM, AUGMENTED
MARKETING STATUS
Discontinued

Products

BETAMETHASONE DIPROPIONATEDiscontinued
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · CREAM, AUGMENTED · TOPICAL

Approval history

2015-06-04Labeling · Supplement 17 · standardAP
2012-11-28Labeling · Supplement 16 · standardAP
2009-07-21Labeling · Supplement 11AP
2009-05-26Labeling · Supplement 10AP
2004-01-23OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →